Synthesis and Evaluation of PDE5 Inhibitory Activity of Novel Pyrido[2′,1′:5,1]pyrazolo[4,3‐d]pyrimidin‐4‐one Derivatives

Novel pyridopyrazolopyrimidinone derivatives were designed and synthesized as potential PDE5 inhibitors. The target compounds demonstrated significant inhibitory activity against human platelet PDE5, but less potent than sildenafil.

[1]  Jingshan Shen,et al.  Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives. , 2005, Bioorganic & medicinal chemistry letters.

[2]  J. Corbin,et al.  Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5) , 2004, Neurochemistry International.

[3]  Weiqin Jiang,et al.  Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors. , 2004, Journal of medicinal chemistry.

[4]  A. Srinivasa Rao,et al.  Synthesis of sildenafil analogues from anacardic acid and their phosphodiesterase-5 inhibition. , 2002, Journal of agricultural and food chemistry.

[5]  Harald Hübner,et al.  Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. , 2002, Journal of medicinal chemistry.

[6]  David P. Rotella,et al.  Phosphodiesterase 5 inhibitors: current status and potential applications , 2002, Nature Reviews Drug Discovery.

[7]  M. El-abadelah,et al.  Synthesis and Vasorelaxant Potency of Monagra. A Chiral 5-(2-Methyl-2,3-dihydro-7-benzofuryl)pyrazolopyrimidone Analog of Viagra® , 2001 .

[8]  S. Lee,et al.  Synthesis and phosphodiesterase 5 inhibitory activity of novel phenyl ring modified sildenafil analogues. , 2001, Bioorganic & medicinal chemistry.

[9]  J. Corbin,et al.  Cyclic nucleotide phosphodiesterases: relating structure and function. , 2001, Progress in nucleic acid research and molecular biology.

[10]  J. Macor,et al.  Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors. , 2000, Journal of medicinal chemistry.

[11]  I R Baxendale,et al.  Polymer-supported reagents for multi-step organic synthesis: application to the synthesis of sildenafil. , 2000, Bioorganic & medicinal chemistry letters.

[12]  L. Lipshultz,et al.  Side-effect profile of sildenafil citrate (Viagra) in clinical practice. , 2000, Urology.

[13]  J. Macor,et al.  N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. , 2000, Journal of medicinal chemistry.

[14]  Truss Mc,et al.  Phosphodiesterase inhibitors in the treatment of erectile dysfunction. , 1998 .

[15]  Andrew Simon Bell,et al.  Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .

[16]  J. Beavo,et al.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. , 1995, Physiological reviews.

[17]  K. Andersson,et al.  Physiology of penile erection. , 1995, Physiological reviews.

[18]  N. Meanwell,et al.  Imidazoquinoline derivatives: potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets. , 1991, Thrombosis research.

[19]  H. W. Hamilton,et al.  Synthesis and structure-activity relationships of pyrazolo[4,3-d]pyrimidin-7-ones as adenosine receptor antagonists. , 1987, Journal of medicinal chemistry.

[20]  M. Shapiro,et al.  1,3-dipolar addition of pyridine N-imine to acetylenes and the use of C-13 NMR in several structural assignments , 1981 .